Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01478581 · ClinicalTrials.gov registry record · Phase 2

Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

A Phase 2 study of Multiple Myeloma, sponsored by Pharmacyclics.

Completed
Registry status
Phase 2
Development phase
92
Enrollment target
11
Study locations

NCT01478581 is a Phase 2 study of Multiple Myeloma that has completed, run by Pharmacyclics. The registered enrollment target is 92 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (83% lower). The trial reports 11 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01478581, a Phase 2 study of Multiple Myeloma, has completed, sponsored by Pharmacyclics.

COMPLETED
Registry status
Phase 2
Development phase
92 participants
Enrollment target
11
Study locations

Study Summary

The primary objective of this study is to determine the efficacy of PCI-32765, both as a single agent and in combination with dexamethasone, in subjects with relapsed or relapsed and refractory Multiple Myeloma (MM)

Conditions Studied

Multiple Myeloma

Interventions

  • DRUG Dexamethasone
  • DRUG PCI-32765

Study Locations (11)

New York

  • SITE-10 - New York
  • SITE-3 - New York

California

  • SITE-13 - La Jolla

Maryland

  • SITE-5 - Baltimore

Massachusetts

  • SITE-4 - Boston

Michigan

  • SITE-8 - Ann Arbor

Missouri

  • SITE-2 - St Louis

New Jersey

  • SITE-6 - Hackensack

Tennessee

  • SITE-1 - Nashville

Trial Details

FieldValue
Enrollment Target 92 participants
Start Date 2012-03
Est. Completion 2018-08
Phase Phase 2

Sponsor

Pharmacyclics

54 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01478581

The ClinicalTrials.gov registry entry for NCT01478581 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (83% lower). The listed sponsor is Pharmacyclics, which has 54 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Dexamethasone is the first listed.

NCT01478581 reports 11 study locations spanning 10 distinct geographic areas - top geographies include New York, California, Maryland.

Frequently Asked Questions

What is clinical trial NCT01478581 about?

NCT01478581 is a clinical study titled "Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma". The primary objective of this study is to determine the efficacy of PCI-32765, both as a single agent and in combination with dexamethasone, in subjects with relapsed or relapsed and refractory Multiple Myeloma (MM)

What is the current status of trial NCT01478581?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 92 participants. The study started on 2012-03. Estimated completion is 2018-08.

What conditions does trial NCT01478581 study?

This clinical trial studies the following conditions: Multiple Myeloma.

What interventions are being tested in trial NCT01478581?

The interventions under investigation include: Dexamethasone (DRUG), PCI-32765 (DRUG).

Who is sponsoring clinical trial NCT01478581?

This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01478581 being conducted?

This trial has 11 study locations across California, Maryland, Massachusetts, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.